comparemela.com

Page 10 - Raquel Cona News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for . Capricor TherapeuticsDecember 29, 2020 GMT LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the independent Data and Safety Monitoring Board (DSMB) has completed its safety review for Capricor’s Phase II INSPIRE study. The DSMB recommended that the study continue as designed with Capricor’s cardiac cell therapy, CAP-1002, for treating patients with severe COVID-19. In addition, an independent prespecified review of the safety data was conducted on an initial group of INSPIRE patients and the study is continui

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.